Citius Pharmaceuticals Inc. Common (CTXR) Stock Price
CTXRStock
$0.60−57.38%52W
Market Cap$16.57M
P/E—
PEG Ratio—
Div yield—
Beta0.98
CTXR Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-31.00%
Price vs S&P 500 (4W)12.49%
VGM Score31.72
CTXR Earnings Surprise History
Q2 25-0.80est. -0.21
Q3 25-0.11est. -0.24
Q4 25-0.38est. -0.30
Q1 26-0.95est. —
Q2 26-0.34est. -0.36
CTXR Analyst Recommendations
May 2026
Jun 2026
Jul 2026
Aug 2026
4.00
4.00
4.00
4.00
Industry Peers — Pharmaceuticals(571)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
CTXRCitius Pharmaceuticals Inc. Common | — | — | D | $0.60 |
| LLYEli Lilly & Co. | D | B | B | $1233.66 |
| JNJJohnson & Johnson | D | C | B | $273.14 |
| ABBVABBVIE INC. | D | C | B | $265.79 |
| MRKMerck & Co., Inc. | D | C | A | $156.45 |
| NVSNovartis AG | C | C | C | $159.98 |
| AZNAstraZeneca PLC | C | B | C | $169.66 |
| NVONovo-Nordisk A/S | B | C | C | $48.66 |
| ABTAbbott Laboratories | C | C | B | $116.13 |
| PFEPfizer Inc. | C | D | C | $28.57 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | $552.85 |
About Citius Pharmaceuticals Inc. Common
Citius Pharmaceuticals develops first-in-class targeted oncology therapies, with LYMPHIR—an engineered IL-2 diphtheria toxin fusion protein—as its flagship product candidate. The company addresses unmet medical needs in oncology and adjunct cancer care with a lower development risk profile than typical new chemical entities.